<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170351</url>
  </required_header>
  <id_info>
    <org_study_id>DDRC-301174</org_study_id>
    <nct_id>NCT01170351</nct_id>
  </id_info>
  <brief_title>Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis</brief_title>
  <official_title>Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Untreated Autoimmune hepatitis (AIH) is a progressive disease. Mainstay of treatment are
      corticosteroids (CS). In addition to being ineffective a substantial minority of cases,
      corticosteroid side-effects hamper effective therapy in another subgroup. Alternative options
      for induction of remission are limited. There are reports of successful salvage therapy with
      Cyclosporine-A (CsA) in steroid refractory cases. In addition, open-labeled studies have
      shown efficacy of Cyclosporine-A in treatment-naive AIH patients. There are no studies
      comparing CsA and CS in a head to head trial. The investigators aim to assess the efficacy
      and tolerability of CsA directly to the CS for induction of remission in treatment-naive AIH
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>12 months</time_frame>
    <description>AST/ALT less than 2x UNL No clinical symptom</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>3 months</time_frame>
    <description>Failure to achieve AST/ALT less than 2x UNL despite adjusting dose according to protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Any adverse event (related or unrelated to the study drug) occuring during the induction phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>Any adverse event requiring hospitalization or leading to disability or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>Group-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment-naive AIH patients consenting to participate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine-A</intervention_name>
    <description>Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.</description>
    <arm_group_label>Group-A</arm_group_label>
    <arm_group_label>Group-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16-65 years old individuals with probable of definite AIH according to the revised AIH
             criteria.

          -  Willing and able to participate in the study

        Exclusion Criteria:

          -  Non-consenting patients

          -  decompensated cirrhosis, i.e. clinical ascites, hepatic encephalopathy, history of
             variceal bleeding

          -  Presence of serious concomitant cardiovascular, pulmonary or renal condition

          -  Presence of active malignant disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Siavosh Nasseri-Moghaddam, MD, MPH</last_name>
    <phone>+98-21-88052286</phone>
    <email>sianasseri@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Malekzadeh, MD</last_name>
    <phone>+98-2188012992</phone>
    <email>rmalekzadeh2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Digestive Disease Research Center, Shariati Hospital</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Malekzadeh, MD</last_name>
      <phone>+98-21-88012992</phone>
    </contact>
    <investigator>
      <last_name>Siavosh Nasseri-Moghaddam, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>July 26, 2010</last_update_submitted>
  <last_update_submitted_qc>July 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Siavosh Nasseri-Moghaddam MD, MPH, Associate Professor of Medicine</name_title>
    <organization>Digestive Disease Research Center, Tehran University of Medical Sciences</organization>
  </responsible_party>
  <keyword>autoimmune hepatitis</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>cysclosporine-A</keyword>
  <keyword>treatment</keyword>
  <keyword>treatment-naive</keyword>
  <keyword>induction of remossion</keyword>
  <keyword>efficacy</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

